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Mexican race is negatively associated with number of doctor visits (P < 0.024). 
CONCLUSIONS: The CHIS database offers an opportunity to investigate the occur-
rence of ER and doctor visits among children with asthma by race and ethnicity. This 
study shows that Mexican children are more likely to have an ER visit and less likely 
to have a doctor visit compared to White children. 
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OBJECTIVES: To evaluate the professional practices and services of the Malaysian 
community pharmacists, using a ‘simulated client’ interview method. The interview 
was carried at two community pharmacists in the state of Penang. METHODS: The 
simulated client (PhD student at the School of Pharmacy, Universiti Sains Malaysia) 
visited two community pharmacists “Pharmacy A” and “Pharmacy B” and asked for 
medications for his and his son’s “viral fever symptoms” respectively. The details were 
documented in a form developed by the researchers. RESULTS: The ﬁ ndings suggested 
a poor professional behavior and dispensing practices among both the pharmacies 
studied. Although, both of them asked the duration of the symptoms, they did not 
ask the age of the patient (s), presence of blood in sputum, previous history of present-
ing medical complaints, past medical history, drug history and smoking status. The 
nature of the sputum was asked only by the pharmacists at pharmacy B. The pharmacy 
A dispensed Tab. Clarithromycin 500 mg, Tab. Paracetamol 500 mg, and Azithromy-
cin powder for suspension 200 mg/5 ml for his son’s viral fever symptoms. The 
pharmacy B dispensed Tab. Cefuroxime 250 mg, Amoxicillin + clavulanic acid powder 
for suspension 125 mg + 31.25 mg/5 ml, Linctus Dextromethorphan + Pro-methacine 
+ Pseudo-ephedrine + Paraben sebagai pengawet, and Tab. Green oats + Sea Buckthom 
+ Stinging Nettle + Tongat Ali + Damiana. The cost of prescription was RM 56.50 
(US$ 16.14) for pharmacy A and RM 129 (US$ 45.15) at pharmacy B. CONCLU-
SIONS: Our ﬁ ndings suggested the need for continuing pharmacy education (CPE) 
programs for the community pharmacists in the country and need for curriculum 
changes incorporating more topics related to community pharmacy practice. Though 
our survey included only two community pharmacies, it can serve as a pilot study for 
future in depth survey encompassing various regions in Malaysia. 
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: Psoriasis is a chronic immune-mediated inﬂ ammatory disorder and is 
associated with concurrence of other complex disorders. This study aims to describe 
the epidemiology of psoriasis and the prevalence of comorbidities in patients with 
psoriasis in Taiwan. METHODS: Patients who had at least one outpatient visit or 
admission diagnosed with ICD-9-CM code 696.0–1 in the Taiwan National Health 
Insurance (NHI) claims database during 2006 were identiﬁ ed as psoriasis cases. The 
cases were further classiﬁ ed into moderate to severe psoriasis (sPsO) for those who 
had previously received systemic therapy and mild psoriasis (mPsO) for those who 
had not. The cases were matched with controls in a 1:4 ratio from one million beneﬁ -
ciaries in the NHI dataset representing the Taiwan population. Matching variables 
included age, gender and residential area. Prevalence of comorbidities was assessed 
using prevalence relative risk (RR) based upon a Cox proportional regression model. 
RESULTS: The prevalence of psoriasis in the overall population was 2.35‰ (n = 
53,761). Mean age (SD) was 46.2 (± 18.6) and 60% were male. Of the 53,761 psoria-
sis cases, 17.2% (n = 9,265) were the sPsO type.sPsO patients had a signiﬁ cantly 
increased prevalence ratio (RR; [95% conﬁ dence interval ])for hypertension (1.33; 
[1.26, 1.40]), diabetes (1.52; [1.42, 1.63]), hyperglyceridemia (1.56; [1.44, 1.69]), 
heart disease (1.24; [1.14, 1.34]), depression (1.44; [1.23, 1.69]), hepatitis B (1.95; 
[1.44, 2.65]) and hepatitis C (2.19; [1.49, 3.22]). Increased risk of these comorbidities 
was also observed in mPsO patients compared to controls, but with a smaller magni-
tude compared to sPsO. CONCLUSIONS: Psoriasis was associated with a signiﬁ cantly 
increased risk of comorbidities, especially for those patients with moderate to severe 
disease. These health consequences should be taken into consideration when evaluat-
ing the burdens of psoriasis and designing effective treatment plans. 
SENSORY SYSTEMS DISORDERS – Cost Studies
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OBJECTIVES: Several methods have been to estimate costs in economic evaluation 
studies. Different methods may give different values. The magnitudes of difference of 
estimates based on cost-to-charge ratio and diagnosis related group (DRG) methods 
were not much investigated. This study aimed to assess the differences of estimates 
of direct medical cost calculated by cost-to-charge ratio and DRG method using 
Stevens—Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN) as a case 
study. METHODS: This study was undertaken with retrospective cohort approach 
using electronic databases of a hospital located in the northern part of Thailand. We 
included patients who came to the hospital between January 1, 2003 and December 
31, 2007 and were coded with International Classiﬁ cation of Disease 10th Edition 
(ICD-10) of L51.1 (SJS) or L51.2 (TEN). We used cost-to-charge ratio and DRG 
methods to estimate direct medical cost of SJS/TEN. All cost estimates were converted 
to reference year (2008) using Thai consumer price index in health product sectors. 
RESULTS: One hundred and ﬁ fty-four patients were included. Mean age was 45.3 
years. Fifty-six percent were male and 93% were SJS patients. The mean and median 
direct medical cost estimated by cost-to-charge ratio was US$918 and US$308, respec-
tively. The mean and median values estimated by DRG were much lower with cost of 
US$554 and US$264, respectively. The mean estimate based on cost-to-charge ratio 
was higher than that of DRG by US$364 or 1.65 times. CONCLUSIONS: The cost 
estimates using cost-to-charge ratio and DRG are different. Selection of cost estima-
tions may impact the cost estimates and cost-effectiveness results. Researchers should 
consider the perspective of study while choosing the method used for estimating costs. 
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OBJECTIVES: Psoriasis is a chronic autoimmune disease that affects approximately 
2.4% of the Taiwanese population. However, little is known about its economic 
burdens. This study estimated those burdens for patients with psoriasis in Taiwan. 
METHODS: Patients who had at least one outpatient visit or admission diagnosed 
with ICD-9-CM code 696.0–1 in the Taiwan National Health Insurance (NHI) claims 
database during 2006 were identiﬁ ed as psoriasis cases. They were further classiﬁ ed 
into moderate to severe psoriasis (sPsO) for those who had previously received sys-
temic therapy and mild psoriasis (mPsO) for those who had not. The cases were 
matched with controls in a 1:4 ratio by age, gender and residential area from a rep-
resentative NHI dataset. Differences in health-care utilization between cases and 
controls were assumed to be attributable to psoriasis. NHI costs were assessed based 
on a two-part model: a logistic regression to predict the probability of use of services 
and a generalized linear model to predict utilization for users of services. Out-of-
pocket costs, transportation costs, and productivity loss from patients and caregivers 
were calculated based on face-to-face patient interviews (n = 327) during July 2009 
to March 2010. All costs were reported in 2009 New Taiwan dollars (1 US$ = 31.91 
NT$). RESULTS: The case-control analysis showed that the NHI cost for patients 
with sPsO and mPsO was 2.34 times and 1.58 times the cost of controls, respectively. 
The total cost due to sPsO was NT$56,885 per patient (70%, 18%, and 12% for 
NHI cost, patient out-of-pocket cost, and productivity loss, respectively). For mPsO, 
the total cost was NT$28,573 (56%, 33%, and 11% for NHI cost, patient out-of-
pocket cost and productivity loss, respectively). Total direct and indirect costs of 
psoriasis are estimated to be NT$1.80 billion annually. CONCLUSIONS: Psoriasis is 
associated with a signiﬁ cant economic disease burden in Taiwan. 
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OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization in patients suffer from glaucoma. METHODS: 
Patients’ self-reported data were collected from 2009 National Health and Wellness 
Survey (NHWS). Survey samples represented major urban areas in China. QOL was 
measured by the physical component score (PCS) and mental component score (MCS) 
of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/
productivity was measured by the validated Work Productivity and Activity Impair-
ment (WPAI) instrument. Medical resource utilization (MRU) was measured by 
health-care provider, emergency room (ER) visits and hospitalization in the past 6 
months. Comparisons were made between respondents who were diagnosed glaucoma 
versus respondents without glaucoma (non-glaucoma group). Since glaucoma typically 
affects adult population, respondents with age 35 and above were included in the 
analysis. RESULTS: Of the 7949 survey respondents with age 35 and above, 85 
